KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Debt (2016 - 2025)

Sarepta Therapeutics has reported Total Debt over the past 16 years, most recently at $829.0 million for Q4 2025.

  • For Q4 2025, Total Debt fell 27.1% year-over-year to $829.0 million; the TTM value through Dec 2025 reached $829.0 million, down 27.1%, while the annual FY2025 figure was $829.0 million, 27.1% down from the prior year.
  • Total Debt for Q4 2025 was $829.0 million at Sarepta Therapeutics, down from $1.1 billion in the prior quarter.
  • Over five years, Total Debt peaked at $1.5 billion in Q4 2022 and troughed at $829.0 million in Q4 2025.
  • A 5-year average of $1.2 billion and a median of $1.1 billion in 2025 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: soared 58.6% in 2021 and later decreased 27.1% in 2025.
  • Year by year, Total Debt stood at $1.1 billion in 2021, then skyrocketed by 40.79% to $1.5 billion in 2022, then decreased by 19.83% to $1.2 billion in 2023, then decreased by 8.15% to $1.1 billion in 2024, then dropped by 27.1% to $829.0 million in 2025.
  • Business Quant data shows Total Debt for SRPT at $829.0 million in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.